8-K: CERO Therapeutics Unveils Novel CAR-T Therapy Safety Data

CERO Therapeutics presents first-in-human clinical data for CER-1236, a TIM-4 based CAR-T therapy, showing a favorable safety profile without cytokine release syndrome.

Summary

• CERO Therapeutics Holdings, Inc. (CERO) filed an 8-K to announce a poster presentation at the Transplantation and Cellular Therapy Meetings on February 4, 2026.
• The poster details the first-in-human clinical experience with CER-1236, a first-in-class chimeric antigen receptor T-cell (CAR-T) therapy.
• CER-1236 is designed to induce phagocytic target clearance through a TIM-4 based receptor ectodomain, targeting TIM-4-L (phosphatidylserine) on apoptotic and cancerous cells, particularly acute myeloid leukemia (AML).
• The therapy's mechanism involves both cytotoxic T cell killing and phagocytosis, differing from traditional cytotoxic CAR-T approaches and aiming for reduced systemic inflammatory toxicity.
• Preclinical safety results showed no off-tumor cytotoxicity, and TIM-4-L expression was high on human AML cells but absent on healthy bone marrow.
• CER-1236 was successfully manufactured and administered to all enrolled patients in the first-in-human trial, demonstrating technical and clinical feasibility.
• No adverse events suggestive of on-target toxicity were observed, and no cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) of any grade occurred.
• No dose-limiting toxicities (DLTs) or treatment-related severe adverse events were observed during the 28-day DLT assessment window.
• An index patient with inv(3) AML received multiple doses of CER-1236 without safety-limiting toxicity, achieving durable platelet recovery and transfusion independence for 72 days.
• Despite platelet recovery, the index patient showed persistent cytogenetic abnormalities, and ultimately experienced rapid disease progression and clinical decline after re-initiation of therapy.
• The study has been expanded to include transfusion-dependent myelodysplastic syndromes (TD-MDS), high-risk MDS (HR-MDS), and myelofibrosis (MF) after JAK inhibitor failure.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a cautiously positive update. The excellent safety profile, particularly the absence of CRS and ICANS, and the successful manufacturing of a novel CAR-T mechanism are strong positives. However, the ultimate disease progression in the index patient tempers enthusiasm for immediate efficacy, though it's a very early-stage trial.

Positives

• CER-1236, a novel CAR-T therapy, was successfully manufactured and administered to all enrolled patients, demonstrating technical and clinical feasibility.
• The therapy exhibited a favorable safety profile in its first-in-human trial, with no observed cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) of any grade.
• No adverse events suggestive of on-target toxicity, dose-limiting toxicities (DLTs), or treatment-related severe adverse events were reported during the 28-day DLT assessment window.
• An index patient with high-risk MDS/AML (inv(3)/Mecom) achieved durable platelet recovery and transfusion independence for 72 days following CER-1236 administration.
• Preclinical data confirmed no off-tumor cytotoxicity and specific targeting of TIM-4-L on AML cells, which is absent on healthy cells.
• The clinical study is being expanded to include additional myeloid disease contexts, such as transfusion-dependent MDS, high-risk MDS, and myelofibrosis, indicating confidence in the therapeutic approach.

Negatives

• Despite initial durable platelet recovery, the index patient with inv(3) AML experienced persistent cytogenetic abnormalities.
• The index patient ultimately experienced a rapid change in disease trajectory, with rising bone marrow blast percentages and progressive functional impairment, leading to end of study due to substantial disease progression and clinical decline.
• One Grade 5 myocardial infarction occurred in a patient after disease progression and initiation of off-protocol chemotherapy, though it was not considered treatment-related.

Risks

• The ultimate efficacy of CER-1236 in achieving deep disease control and sustained remission remains to be fully demonstrated, as evidenced by the disease progression in the index patient despite initial positive hematologic response.
• While not deemed treatment-related, serious adverse events such as febrile neutropenia, tumor lysis syndrome, generalized weakness, and myocardial infarction were observed in the safety analysis set, highlighting the fragility of the patient population.

Future Outlook

The company plans to further evaluate CER-1236 in additional myeloid disease contexts characterized by chronic inflammatory bone marrow microenvironments and elevated TIM-4L expression, including myelodysplastic syndromes (MDS) and myelofibrosis (MF). The hypothesis is that TIM-4 mediated recognition and clearance of TIM-4L cells and cellular debris may help reprogram the inflammatory marrow niche and support normal hematopoiesis.

Management Comments

• "CER-1236, a first-in-class phagocytic CAR-T therapy targeting TIM-4 ligand (TIM-4L), was successfully manufactured and administered to all enrolled patients in a first-in-human trial, demonstrating the technical and clinical feasibility of this novel therapeutic approach."
• "In this first CAR-T experience targeting TIM-4L, no adverse events suggestive of on-target toxicity were observed, supporting further clinical development of this approach."
• "No cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) of any grade was observed, despite incorporation of a CD28 costimulatory domain and measurable cell expansion, consistent with a non-cytotoxic, phagocytosis-driven mechanism of action."
• "Collectively, these findings support clinical evaluation of CER-1236 in additional myeloid disease contexts characterized by chronic inflammatory bone marrow microenvironments and elevated TIM-4L expression, including myelodysplastic syndromes (MDS) and myelofibrosis (MF)."

Industry Context

StockSavvy.ai notes that the CAR-T therapy landscape is highly competitive and rapidly evolving, primarily focused on cytotoxic T-cell mechanisms. CER-1236's novel phagocytosis-driven mechanism, targeting TIM-4L, represents a differentiated approach that aims to reduce systemic inflammatory toxicity, a common and severe side effect of conventional CAR-T therapies. This could position CERO Therapeutics favorably if the efficacy can be consistently demonstrated in larger patient cohorts.

Comparison to Industry Standards

• The absence of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) of any grade for CER-1236 is a significant positive differentiator compared to many approved CAR-T therapies, such as Novartis' Kymriah (tisagenlecleucel) or Gilead's Yescarta (axicabtagene ciloleucel), which frequently report Grade 3 or higher CRS and ICANS.
• The successful manufacturing of CER-1236 using a 7-day process on a Miltenyi Prodigy platform is comparable to or potentially more efficient than some established CAR-T manufacturing timelines, which can vary from 10-21 days.
• While the durable platelet recovery in the index patient is encouraging, the ultimate disease progression highlights the challenge of achieving complete and sustained remission in high-risk myeloid malignancies, a hurdle faced by many experimental therapies in this difficult-to-treat patient population.

Stakeholder Impact

• **Shareholders:** The positive safety profile and expansion of the study could increase investor confidence in the long-term potential of CER-1236, despite mixed efficacy signals in the single detailed patient case.
• **Patients:** Offers a potentially safer CAR-T option for patients with advanced myeloid malignancies, particularly those who cannot tolerate the toxicity of existing CAR-T therapies.
• **Medical Community:** Introduces a novel CAR-T mechanism (phagocytic, TIM-4 based) that could open new avenues for treating hematologic cancers with reduced inflammatory side effects.

Next Steps

• Clinical evaluation of CER-1236 in additional myeloid disease contexts, including transfusion-dependent myelodysplastic syndromes (TD-MDS), high-risk MDS (HR-MDS), and myelofibrosis (MF) after JAK inhibitor failure.

Key Dates

Recommendation

The filing presents promising early-stage safety data for a novel CAR-T therapy, with no CRS or ICANS, which is a significant advantage. However, the efficacy data, particularly the ultimate disease progression in the detailed index patient, is mixed and very limited. Given the early phase (first-in-human) and the need for further clinical validation in larger cohorts, a 'hold' recommendation is appropriate for a seasoned investor, balancing the strong safety profile and novel mechanism against the unproven long-term efficacy.

Keywords

CAR-T therapy, CER-1236, TIM-4, acute myeloid leukemia, AML, myelodysplastic syndromes, MDS, myelofibrosis, MF, clinical trial, oncology, hematology, biotechnology, SEC filing